Precigen Inc (PGEN) FinancialsPGENPrecigen Inc

Precigen, Inc. (PGEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product, accounting for 96.9% of total sales, equivalent to $53.26M. Another important revenue stream is Service. Understanding this composition is critical for investors evaluating how PGEN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Precigen, Inc. maintains a gross margin of 94.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 41.18%, while the net margin is 36.51%. These profitability ratios, combined with a Return on Equity (ROE) of -9907.46%, provide a clear picture of how effectively PGEN converts its operational activities into shareholder value.

In the context of the broader market, PGEN competes directly with industry leaders such as AUPH and MBX. With a market capitalization of $2.38B, it holds a significant position in the sector. When comparing efficiency, PGEN's gross margin of 94.90% stands against AUPH's 92.12% and MBX's N/A. Such benchmarking helps identify whether Precigen, Inc. is trading at a premium or discount relative to its financial performance.

Precigen reported a remarkable revenue growth of 145% in Q2 2026, driven primarily by its FDA-approved product Papzimeos, which generated $53.1 million in sales. The gross margin for the same quarter was an impressive 94.90%, showcasing strong profitability potential.